We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
(+14%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
5.76%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$128M |
| 2 |
Intel
INTC
|
+$88.4M |
| 3 |
Prudential Financial
PRU
|
+$72.7M |
| 4 |
Lam Research
LRCX
|
+$62.6M |
| 5 |
SBA Communications
SBAC
|
+$58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$98.3M |
| 2 |
Target
TGT
|
+$86.8M |
| 3 |
Occidental Petroleum
OXY
|
+$74.7M |
| 4 |
Synchrony
SYF
|
+$61.6M |
| 5 |
Intercontinental Exchange
ICE
|
+$57.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 13.54% |
| 3 | Financials | 13.08% |
| 4 | Consumer Discretionary | 12.97% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
801
Elicio Therapeutics
ELTX
$78.8M
| $744K | 0.01% |
+5,715
| New | +$824K |
|
802
First Western Financial
MYFW
$311M
| $739K | 0.01% |
28,531
+1,888
| +7% | +$50.4K |
|
|
ZUO
803
DELISTED
Zuora, Inc.
ZUO
| $738K | 0.01% |
+42,793
| New | +$684K |
|
804
Central Garden & Pet Co Class A
CENTA
$2.41B
| $729K | ﹤0.01% |
18,865
-182,443
| -91% | -$7.48M |
|
805
Bank of Marin Bancorp
BMRC
$466M
| $720K | ﹤0.01% |
22,577
+10,941
| +94% | +$383K |
|
806
Geospace Technologies
GEOS
$91.6M
| $713K | ﹤0.01% |
88,103
-7,865
| -8% | -$64.7K |
|
|
SGTX
807
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $709K | ﹤0.01% |
+5,084
| New | +$893K |
|
808
Ducommun
DCO
$2.68B
| $707K | ﹤0.01% |
12,953
-2,099
| -14% | -$119K |
|
|
GPX
809
DELISTED
GP Strategies Corp.
GPX
| $705K | ﹤0.01% |
+44,846
| New | +$727K |
|
810
Community Health Systems
CYH
$385M
| $702K | ﹤0.01% |
+45,455
| New | +$618K |
|
811
Churchill Downs
CHDN
$6.03B
| $699K | ﹤0.01% |
+7,048
| New | +$724K |
|
812
Metallus
MTUS
$873M
| $699K | ﹤0.01% |
49,429
-357,077
| -88% | -$4.82M |
|
|
HIL
813
DELISTED
Hill International, Inc. Common Stock
HIL
| $694K | ﹤0.01% |
278,636
-70,534
| -20% | -$188K |
|
814
Kulicke & Soffa
KLIC
$5.3B
| $692K | ﹤0.01% |
11,302
-190,024
| -94% | -$10.2M |
|
|
ITOS
815
DELISTED
iTeos Therapeutics
ITOS
| $672K | ﹤0.01% |
+26,205
| New | +$624K |
|
816
SEI Investments
SEIC
$11.9B
| $667K | ﹤0.01% |
+10,761
| New | +$671K |
|
817
Veeva Systems
VEEV
$30.3B
| $664K | ﹤0.01% |
+2,135
| New | +$595K |
|
818
Globe Life
GL
$13.5B
| $660K | ﹤0.01% |
+6,924
| New | +$709K |
|
819
Kiniksa Pharmaceuticals
KNSA
$4.83B
| $657K | ﹤0.01% |
47,178
-3,335
| -7% | -$50.7K |
|
|
ACOR
820
DELISTED
Acorda Therapeutics
ACOR
| $645K | ﹤0.01% |
6,760
-5,696
| -46% | -$498K |
|
821
Enterprise Financial Services Corp
EFSC
$2.41B
| $644K | ﹤0.01% |
13,887
| – | – |
|
822
Energizer
ENR
$1.44B
| $637K | ﹤0.01% |
14,829
-32,522
| -69% | -$1.52M |
|
823
Biglari Holdings Class B
BH
$1.2B
| $635K | ﹤0.01% |
3,983
-660
| -14% | -$102K |
|
|
RUBY
824
DELISTED
Rubius Therapeutics, Inc
RUBY
| $634K | ﹤0.01% |
25,981
-12,565
| -33% | -$314K |
|
825
Townsquare Media
TSQ
$113M
| $625K | ﹤0.01% |
49,008
+13,233
| +37% | +$157K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2021 Portfolio in Review
As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.
- Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
- Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
- Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
- Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
- Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.